Exclusive Summary

• Patent & Exclusivity: As a Class 1 novel drug approved in China in 2026, it offers long-term patent protection and market exclusivity, allowing distributors to entirely avoid the cutthroat generic price wars typical of standard analgesics.
• Massive Market Demand: Precisely targets the global acute and post-operative pain market driven by over 310 million major surgeries annually, perfectly aligning with the urgent global healthcare trend of opioid-sparing pain management.
• Fast-Track Registration & High Margins: Backed by comprehensive clinical data from China's NMPA (an ICH member), it enables accelerated regulatory approvals in emerging markets (SEA, LATAM, CIS) and leverages 'innovative quality + Chinese manufacturing costs' to guarantee substantial profit margins for local partners.